SPDR S&P Biotech ETF (XBI) Holdings Lifted by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. grew its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 9.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 15,938 shares of the exchange traded fund’s stock after buying an additional 1,364 shares during the period. Stratos Wealth Partners LTD.’s holdings in SPDR S&P Biotech ETF were worth $1,528,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Morgan Stanley raised its holdings in SPDR S&P Biotech ETF by 23.8% in the second quarter. Morgan Stanley now owns 9,568,839 shares of the exchange traded fund’s stock worth $910,858,000 after buying an additional 1,840,100 shares during the last quarter. Assetmark Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 271,147.4% during the second quarter. Assetmark Inc. now owns 1,264,013 shares of the exchange traded fund’s stock valued at $120,321,000 after purchasing an additional 1,263,547 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of SPDR S&P Biotech ETF by 159.3% during the second quarter. SG Americas Securities LLC now owns 977,702 shares of the exchange traded fund’s stock valued at $93,067,000 after purchasing an additional 600,603 shares during the last quarter. First Republic Investment Management Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 17.2% during the second quarter. First Republic Investment Management Inc. now owns 515,072 shares of the exchange traded fund’s stock valued at $49,030,000 after purchasing an additional 75,665 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of SPDR S&P Biotech ETF by 19.5% during the third quarter. Bank of Montreal Can now owns 229,588 shares of the exchange traded fund’s stock valued at $22,011,000 after purchasing an additional 37,396 shares during the last quarter.

XBI opened at $84.21 on Friday. SPDR S&P Biotech ETF has a twelve month low of $76.37 and a twelve month high of $101.55.

TRADEMARK VIOLATION WARNING: This article was originally published by WKRB News and is the property of of WKRB News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.wkrb13.com/2018/11/09/spdr-sp-biotech-etf-xbi-holdings-lifted-by-stratos-wealth-partners-ltd.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply